CUSN
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Copper Search Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
2
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Copper Search Limited - Ordinary Fully Paid Deferred
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in CUSN
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in CUSN
N/A
CUSN investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in CUSN also invest in...
IEM.AX was created on 2003-04-07 by iShares. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the equity market performance in global emerging markets.
🙌 Performance (5Yr p.a)
3.50%
📊 Share price
$69.50 AUD
🌏 GLOBAL
VGE.AX was created on 2013-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Seeks to track the return of the FTSE Emerging Markets All Cap China A Inclusion Index in Australian dollars, before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
4.31%
📊 Share price
$79.87 AUD
🌏 GLOBAL
⛳️ DIVERSIFIED
PMGOLD
PMGOLD.AX was created on 2003-05-09 by Perth Mint. The fund's investment portfolio concentrates primarily on gold commodities. PMGOLD.AX is designed to track the international price of gold in Australian dollars and offers investors a simple, low cost way to access the returns on gold.
🙌 Performance (5Yr p.a)
15.94%
📊 Share price
$46.00 AUD
📈 HIGH PRICE GROWTH
FOOD.AX was created on 2016-08-02 by BetaShares. The fund's investment portfolio concentrates primarily on theme equity. The Investment objective of the Betashares Global Agriculture Companies ETF - Currency Hedged is to provide an investment returns that aims to track the performance of the Nasdaq Global ex - Australia company hedged AUD Index.
🙌 Performance (5Yr p.a)
7.28%
📊 Share price
$6.41 AUD
🌏 GLOBAL
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
6.30%
📊 Share price
$67.63 AUD
⛳️ DIVERSIFIED
🌏 GLOBAL
Want more shares? Try these...
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).
🙌 Performance (5Yr p.a)
-4.56%
📊 Share price
$11.85 AUD
🧬 BIOTECHNOLOGY
